This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Biosimilar insulins: a European perspective

Biosimilar insulins: a European perspective

Read time: 1 mins
Published:25th Mar 2020
?Biosimilar insulins are likely to enter clinical practice in Europe in the near future. It is important that clinicians are familiar with and understand the concept of biosimilarity and how a biosimilar may differ from its reference product. This article provides an overview of biosimilars, the European regulatory requirements for biosimilars and safety issues. It also summarises the current biosimilars approved in Europe and key clinical issues associated with the use of biosimilar insulins.

Read abstract on library site